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Background: The identification of circulating endothelial progenitor cells (EPCs) has introduced new possibilities for
cell-based treatments for stroke. We tested the angiogenic gene expression of outgrowth endothelial cells (OECs),
an EPC subtype capable to shape vessel structures.
Methods: OECs (at colony or mature stages) from ischemic stroke patients (n=8) were characterized using the RT2
ProfilerTM human angiogenesis PCR Array, and human microvascular endothelial cells (hCMEC/D3) were used as an
expression reference of endothelial cells.
Results: Colony-OECs showed higher expression of CCL2, ID3, IGF-1, MMP9, TGFBR1, TNFAIP2, TNF and TGFB1.
However, BAI-1, NRP2, THBS1, MMP2 and VEGFC expression was increased in mature-OECs (p<0.05). ID3 (p=0.008)
and TGFBR1 (p=0.03) genes remained significantly overexpressed in colony-OECs compared to mature-OECs or
hCMEC/D3. MMP9 levels were significantly increased in colony-OECs (p=0.025) compared to mature-OECs.
Moreover, MMP-2, VEGF-C, THBS1 and NRP-2 gene expression was also significantly increased in mature-OECs
compared to hCMEC/D3 (p<0.05). Some of these genes were positively validated by RT-PCR.
Conclusion: Our study shows that OECs from stroke patients present higher levels of pro-angiogenic factors at
early stages, decreasing in mature OECs when they become more similar to mature microvascular endothelial cells.
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Endothelial progenitor cells (EPCs) is a minor popula-
tion of circulating mononuclear cells that participates
in adult neovascularization in pathological and physio-
logical processes. Current research on EPCs in adults
holds great promise and is receiving much attention due
to their contribution to neoangiogenesis in vascular in-
juries, such as wound healing, limb ischemia, myocardial
infarction, atherosclerosis or stroke [1].
An approach to isolate EPCs from peripheral blood
utilizes in vitro culture and produces two distinct EPC
subtypes which have been named circulating angiogenic* Correspondence: anna.rosell@vhir.org
1Neurovascular Research Laboratory and Neurovascular Unit. Neurology and
Medicine Department, Universitat Autònoma de Barcelona. Vall d’Hebron
Research Institute of Vall d’Hebron Hospital, Pg Vall d’Hebron 119-129,
Barcelona 08035, Spain
Full list of author information is available at the end of the article
© 2013 Navarro-Sobrino et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumcells or “early EPCs” (eEPCs) and “outgrowth endothelial
cells” (OECs). OECs are also known as endothelial
colony-forming cells (ECFCs) or late EPCs because of
their late appearance in culture and their ability to grow
from expanding colonies [2]. OECs have been directly
involved in vascular repair by forming perfused human
neo-vessels when injected subcutaneously into immune
deficient mice [3]. It has already been demonstrated that
OECs are more efficiently isolated from ischemic stroke
patients than control subjects together with their ability
to shape capillary-like structures in vitro [4]. For the
specific purpose of vascular disease modelling, OECs
should be the preferred EPC subtype to use, and a better
understanding of their angiogenic characteristics in their
different stages could be very useful to assess their re-
generative potential in cell based therapies for ischemic
stroke patients. However, the molecular features thatd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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are still unknown.
To better understand the molecular program of
OECs in ischemic stroke, our aim was to examine the
angiogenesis-related gene expression profile of OECs
from ischemic stroke patients at initial colony (colony-
OECs) or mature stages (mature-OECs), and compared
them to mature human cerebral microvascular endo-
thelial cells (hCMEC/D3) as a reference of endothelial
cell expression.Materials and methods
Ethics statement
The study was approved by the Ethics Committee of our
institution and conducted in accordance with the Dec-
laration of Helsinki. All patients or relatives and healthy
controls gave written informed consent.Figure 1 Representative cell culture images and gene expression pro
of colony-OECs (40× magnification) and mature-OECs (100x magnification)
B) Heat maps illustrating gene-expression profile of patients included in co
indicates low expression and the red color indicates high expression.Isolation and culture EPCs
Peripheral blood (20 ml) was obtained in EDTA-
anticoagulated tubes from patients who had suffered a
non-lacunar ischemic stroke (n=8) involving the middle
cerebral artery (MCA) territory between 24 h and 7 days
after onset of symptoms, and who had been admitted to
the emergency department of our center. OECs were iso-
lated from peripheral blood as previously described [4].
Colony-OECs appeared as rounded expanding colonies,
while later acquisition of confluent cobblestone-shaped in
monolayers was identified as mature-OECs (Figure 1A).
hCMEC/D3 cells, which are derived by immortalization
of human brain primary microvascular endothelial cells
were grown as previously described [5]. Additionally,
EPCs from sex- and age-matched control subjects free
of ischemic events, inflammatory or infectious diseases
(n=17) were initially cultured but cell cultures did not
yield OEC cells.file of the studied cells. A) Representative phase contrast images
from ischemic stroke patients and hCMEC/D3 (100× magnification).
lony-OECs, mature-OECs and hCMEC/D3 groups. The green color
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obtained from each patient and all were scored for
stroke severity and neurological status on admission and
on follow-up visits according to the National Institutes
of Health Stroke Scale (NIHSS). Functional outcome
was defined by modified Rankin Scale (mRS) at three
months and patients with mRS >2 points were consid-
ered functionally dependent.
RNA isolation and quality control
RNA was obtained from cell cultures for both early-
colony stage OECs and mature OECs. Since those cells
obtained from the colony stage were not further
expanded, different patients were included in the
mature-OECs group. The RNA from the mature-OECs
was isolated from cells between the 4th and 10th pas-
sage since after 12 population doublings mature-OECs
started to change their morphology probably undergo-
ing to senescence. The colony-OECs were isolated be-
fore the first passage was done. Finally, hCMEC/D3
cells line was included as a reference of human endo-
thelial cell type.
Colony-OECs obtained from ischemic stroke patients
(n=3) were isolated using a cell scraper. Mature-OECs
(1×105 cells/mL) taken between passages 4 and 10 from
ischemic stroke patients (n=5) and hCMEC/D3 (1×105
cells/mL) at different passages (from 32 to 34; n=3) were
seeded in twelve-well plates with EGM-2 (CloneticsW,
CA, USA) and maintained until confluence reached
about 90%. A total of 11 samples were included in the
study. Total RNA was extracted with the RNeasy Mini
kit (Qiagen, CA, USA). The RNA concentration and
quality were measured using the Bioanalyzer 2100 sys-
tem (Agilent, CA, USA). All samples presented high-
quality RNA with RNA integrity numbers above 8.5.
cDNA was pre-amplified using RT2 Nano PreAmp
cDNA Synthesis Primer Mix Human Angiogenesis kits
according to manufacturer’s instructions (SabBioscience,
Qiagen). RT2 Profiler™ human angiogenesis PCR array
was performed for quantitative PCR in the ABI 7000
system (Applied Biosystems, USA) with the following
cycling conditions; 10 min at 95°C, 15 s at 95°C, 1 min
60°C for 40 cycles with a final infinite 4°C hold.
Data normalization
Five endogenous control genes [glucuronidase β (GUS β),
hypoxanthine guanine (HPRT1), heat-shock protein
90 (HSP90), glyceraldehyde phosphate dehidrogenase
(GAPDH), and β-actin (ACT β)] present on the RT2
Profiler™ human angiogenesis PCR Array were used
for data normalization. Each replicate cycle threshold
(Ct) was normalized to the geometric median Ct of 5 en-
dogenous controls per plate. Ct was defined as 35 for the
ΔCt calculation when the signal was under detectablelimits. The relative amount of transcripts in the colony-
OECs and mature-OECs samples was calculated com-
pared to our expression reference in hCMEC/D3. Results
were calculated using the 2-ΔΔCt method [6]. Changes in
gene expression between colony-OECs, mature-OECs and
hCMEC/D3 cells are shown as a fold increase or decrease.
Heat maps (color-coded graphs with groups in columns
and genes in rows) were generated by using the web
based program of RT2 profiler PCR Array Data Analysis.
Real time PCR analysis
Quantitative Real-time PCR (qRT-PCR) was used to meas-
ure mRNA expression levels of MMP2, MMP9, VEGF-C,
NRP-2 and THBS1 as a validation of the array data. Those
probes were available in our laboratory, therefore the selec-
tion of genes for validation was random and not depend-
ant on the significance level or the fold change. The same
samples (n=11) used in the RT2 Profiler™ human angio-
genesis PCR Array were included. The mRNA levels were
quantified using TaqMan Hs00234422_m1 MMP2 (for
MMP2), Hs00234579_m1 MMP9 (for MMP9), VEGFC
Hs00153458_m1 VEGFC (for VEGF-C), Hs00962908_m1
THBS1 (for THBS1), Hs00187290_m1 NRP2 (for NRP-2)
and Hs00181777_m1 BAI1 (for BAI1). The expression of
the housekeeping gene peptidylprolylisomerase A (PPIA;
probe Hs99999904_m1) was quantified as a reference to
normalize all values. Real-time PCRs were run in triplicate
and analyzed using the Applied Biosystems SDS 7500
system software (Applied Biosystems). The results are
expressed as percentages based on a calibration sample
used in all experiments.
Statistical analysis
The statistical significance was set at p value less than
0.05 and a mean difference equal to or greater than
2-fold change in expression levels. Normal distribution
of the variables was tested using the Shapiro-Wilk test.
Differences between colony-OECs, mature-OECs and
hCMEC/D3 groups were determined using the One-Way
ANOVA or Kruskal Wallis and Mann Whitney tests for
normal and non-normal distributions, respectively. Data
were expressed as mean fold change ± SD for normal
distributed variables or median (interquartile range) for
non-normal distributed variables. All statistical analyses
were performed with SPSS version 15.0 software. To ac-
count for multiple statistical testing, false discovery rate
(FDR) q-values were calculated.
Results
The stroke patients included in the study were under
different secondary prevention treatments. One patient
in each study-group was receiving oral anticoagulation
therapy, 2 patients in colony-OECs and 3 in mature-
OECs group were under antiplatelet agents. In addition,
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group were under statins. Moreover, a patient in the
colony-OECs group showed a previous stroke.
Baseline NIHSS was similar in patients from colony-
OECs and mature-OECs groups (14 ± 7.2 vs. 8.2 ± 5.8;
p=0.297 respectively) and also NIHSS at discharge (12.3 ±
6.5 vs. 11.6 ± 15.9; p=0.513 respectively). Regarding func-
tional outcome no differences were found between
patients from colony-OECs and mature-OECs groups
(4 ± 2 vs. 2.4 ± 2.2; p=0.263 respectively). None of the
analyzed genes showed any correlation between their ex-
pression level and the clinical outcome. White blood cell
counts of the stroke patients included in the study were
not statistically different (p=0.65).
The Human Angiogenesis RT2 Profiler PCR Array
profiles the expression of 84 key genes involved in the
biological processes of angiogenesis. Over 90% of the
transcripts (n= 75) were detected whereas the expression
of ANGPT1, CXCL9, IL8, COL18A1, COL4A3, CCL11,
HAND2, IFN-G and TIMP-3 was undetected by this
technique. Quality control parameters included in the
Human Angiogenesis RT2 Profiler PCR Array (positive
PCR controls and reverse transcription controls) showed
a good reproducibility and efficiency based on the web
based program of RT2 profiler PCR Array Data Analysis.
Overall, the analysis of the heat maps showed that
mature-OECs gene-expression pattern partially matched
hCMEC/D3 (Figure 1B). Our results showed that in
the colony-OECs group, 45 genes were overexpressed
whereas only 13 genes were underexpressed. Similarly,
the mature-OECs group showed 31 genes overexpressed
and 15 underexpressed compared to hCMEC/D3 cells.Table 1 Identification of differentially expressed transcripts b
D3 cells
Symbol Gene name Colony-OECs fo
ID3 Inhibitor of DNA binding 3 4.5 ±
TNFAIP2 Tumor necrosis factor alpha-induced protein 2 47.2 (13
TGFβR1 Transforming growth factor beta receptor 1 3.5 (3
TGFβ1 Transforming growth factor beta 1 2.2 ±
CCL2 Chemokine (C-C motif) ligand 2 48.7 (28
THBS1 Thrombospondin 1 22.7 (
BAI 1 Brain-specific angiogenesis inhibitor 1 43 (12
MMP2 Matrix metallopeptidase 2 508.7 (30
NRP2 Neuropilin 2 76.9 (2
TNF Tumor necrosis factor 320.4 (3
IGF1 Insulin-like growth factor 1 11393.9 (168
VEGFC Vascular endothelial growth factor C 5.7
MMP9 Matrix metalloprotease 9 2125.8 (62
Data are expressed as mean fold change ± SD or median (interquartile range) as ap
* p<0.05 and fold change ≥2 Colony-OECs or Mature-OECs vs hCMEC/D3 cells; # p<At the same time, we only identified 13 genes displaying
a significantly different expression between colony-OECs
and mature-OECs and all of them were overexpressed in
OECs compared to hCMEC/D3 as shown in Table 1.
CCL2 showed an increase in colony-OECs compare
to mature-OECs or hCMEC/D3 cells [fold change 48.7
(28–117); p=0.036]. ID3 was also increased in colony-OECs
when compared to others groups [fold change 4.5 ± 0.4;
p=0.008]. Moreover, IGF-1 and MMP9 were also overex-
pressed in colony-OECs compared to both mature-OECs
and hCMEC/D3 [fold change 11393.9 (1682–13738) and
2125.8 (627–2563), respectively] as shown in Table 1. TNF
and TGFβ1 showed higher gene expression [fold change
320.4 (39–531) and 2.2 ± 0.2, respectively] in colony-OECs
compared to hCMEC/D3. Interestingly, TGFβR1 and
TNFAIP2 also showed an increase [fold change 3.5 (3–28)
and 47.2 (13–455), respectively] only in colony-OECs com-
pared to mature-OECs.
On the other hand, we observed a significant increase
in BAI-1 in mature-OECs compared to hCMEC/D3 [fold
change 14.2 (2–33); p=0.037]. Similarly, our results
showed that NRP2, THBS1 and VEGFC were increased in
mature-OECs when compared to hCMEC/D3 [fold
change 12.7 (9–238); 5.8 (3–9) and 5 (3–9), respectively]
as shown in Table 1. Finally, only the expression of
MMP2 was overexpressed in both colony-OECs and
mature-OECs compared to hCMEC/D3 [fold change
508.7 (306–600) and 67.2 (32–595), respectively]. After
performing Bonferroni post-test analysis for multiple
comparisons in normal-distributed genes, only ID3 and
TGFβR1 genes remained significantly overexpressed in
colony-OECs compared to mature-OECs or hCMEC/D3.etween the Colony- or Mature-OECs compared to hCMEC/
ld change (n=3) Mature-OECs fold change (n=5) p value q value
0.4 *# 2.1 ± 1.4 0.008 0.750
-455) # 3.9 (1-9) 0.018 0.750
-28) # 1.8 (0.7-2) 0.030 0.750
0.2 * 1.4 ± 0.7 0.036 0.750
-117) *# 12.8 (0.7-20) 0.036 0.500
19-23) 5.8 (3-30) * 0.037 0.375
-103) 14.2 (2-33) * 0.037 0.600
6-600) * 67.2 (32-595) * 0.042 0.333
2-185) 12.7 (9-238) * 0.043 0.300
9-531) * 0.9 (0.5-9) 0.046 0.313
2-13738) *# 1.4 (0.8-8) 0.046 0.341
(2-6) 5 (3-9) * 0.048 0.268
7-2563)*# 0.6 (0.1-2) 0.049 0.250
propriate.
0.05 and fold change ≥2 Colony-OECs vs Mature-OECs.
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on all distributed genes analyzed, none of the q values
obtained was statistically significant (Table 1).
To validate our results by another technique MMP2,
MMP9, VEGF-C, THBS1 and NRP-2 mRNA expression
was measured using qRT-PCR. Figure 2A shows that
MMP9 levels were significantly increased in colony-
OECs (p=0.025) compared to mature-OECs and also
overexpressed compared to hCMEC/D3 (p=0.05). In
colony-OECs we also observed a trend to increased
MMP2 levels compared to hCMEC/D3 (p=0.05) and a
significant overexpression in mature-OECs compared to
hCMEC/D3 (p=0.025); see Figure 2B. Moreover, VEGF-
C, THBS1 and NRP-2 gene expression was also signifi-
cantly increased (p=0.034) in mature-OECs compared to
hCMEC/D3 as shown in Figure 2.
This data confirms the results obtained in the RT2
profiler PCR Array and validates the analysis.
Discussion
This study reveals for the first time the angiogenic gene-
expression profile of OECs from ischemic stroke
patients. Our results show that early colony-OECs fromFigure 2 Validation of MMP2, MMP9, VEGF-C, THBS1 and NRP2 mRNA
mature-OECs (n=5). B) MMP2 mRNA levels in colony-OECs (n=3) and matur
and hCMEC/D3 (n=3). D) THBS1 mRNA levels in mature-OECs (n=4) and hC
(n=3). Expression level is relative to calibrator sample and dashed line indic
mature-OECs); # p<0.05 (vs. hCMEC/D3).ischemic stroke patients display higher expression of
proangiogenic-related genes, while expression of these
set of genes in more mature populations (mature-OECs)
is more similar to human cerebral microvascular endo-
thelial cells.
A recent study has revealed changes in gene expres-
sion of late outgrowth EPC-derived endothelial cells
from systemic sclerosis patients that could contribute to
the endothelial dysfunction and may be relevant to the
development of the vasculopathy [7]. However, it is com-
pletely unknown the gene expression profile of EPCs
from ischemic stroke patients.
Other authors have studied the differentiation process
of cord blood-derived EPCs showing that the first stage
involves the expression of genes related to cell adhesion
to extracellular matrix; during the second stage, gene-
expression profile reveals transcription of cell cycle and
antiapoptotic genes; finally, after the proliferative stage,
adherent EPCs acquire additional endothelial-specific
characteristics through the expression of endothelial
markers [8]. Our results in the present study show that
some of the genes previously described as expressed in
EPCs from cord blood or peripheral blood of healthylevels by qRT-PCR. A) MMP9 mRNA levels in colony-OECs (n=3) and
e-OECs (n=5). C) VEGF-C gene expression levels in mature-OECs (n=4)
MEC/D3 (n=3). E) NRP-2 mRNA in mature-OECs (n=4) and hCMEC/D3
ates median expression for hCMEC/D3 reference. * p<0.05 (colony vs.
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are also expressed in EPCs from ischemic stroke patients.
Additionally, it is known that IGF-1 is highly expressed in
EPCs compared to mature endothelial cells or monocytes
enhancing EPC differentiation involving PI3-kinase/phos-
phorylated Akt pathways of cell survival and proliferation
[10,11]. Our data also confirms that IGF-1 mRNA level
is also increased in colony-OECs derived from stroke
patients, suggesting a role for IGF-1 during the differenti-
ation process of these cells.
Furthermore, it is well established that secreted matrix
metalloproteinases (MMPs) from EPCs have a pivotal
role in the ischemia-induced neovascularization since
they actively participate in matrix degradation [12]. In
this context, we show that MMP9 and MMP2 are highly
expressed in colony-OECs, further reinforcing the func-
tional properties of this population. We also success-
fully validated the MMP2, MMP9, VEGF-C, THBS1
and NRP-2 results by qRT-PCR showing that the RT2
profiler PCR Array is a good method to assess gene
expression levels even when differences in expression
are small.
In addition, our findings also prove the overexpression
of ID3 and TGFβR1 genes in colony-OECs, suggesting a
role in the proliferation and differentiation of colony-
OECs to endothelial cells. In fact, previous reports have
demonstrated that ID3 −/− mutant mice show a mark-
edly impaired EPC mobilization [9] and TGFβR1 has
also been involved in the mobilization and differenti-
ation of cord blood-derived EPCs [13]. Recently, the
capacity of EPCs to support the activity and function of
resident differentiated cells by paracrine mechanisms has
focused increased attention [14]. Our study also demon-
strates that colony-OECs show a higher proangiogenic
gene expression pattern, suggesting that colony-OECs
could potentially present a higher secretion of angiogenic
growth factors.
The current study has revealed that the gene expres-
sion profile of mature-OECs from ischemic stroke
patients partially resembles that of hCMEC/D3 cells.
Recently, it has been reported that OECs acquire add-
itional endothelial-specific characteristics based on
transcriptomic-, proteomic-, and ultrastructural- ana-
lysis [15]. Consistent with that study, our results also
demonstrate that mature-OECs show an increase in
MMP2, THBS1 and VEGF-C, reinforcing the endothelial
nature of mature-OECs. Interestingly, we also observe
an increase in mature-OECs expression of BAI-1, a
member of the secretin receptor family involved in the
inhibition of angiogenesis, supporting the hypothesis
that angiogenesis is controlled by a local balance be-
tween stimulators and inhibitors.
In the context of cerebral ischemia, the first pre-
clinical studies testing the therapeutic potential of EPCsadministrated early EPCs [16,17] but lately, new studies
are exploring the role of OECs [18]. It is important to
define the nature of these cells in culture to identify the
best population for transplantation.
A recent publication demonstrated that time in culture
conditions did not alter phenotype of OECs with no sig-
nificant change in antigen expression between early
(passage 0–2), mid (passage 4–6) and late passage
(passage 6–9) cells. Furthermore, they confirmed that late
outgrowth endotelial progenitor cells resembled mature
human umbilical vein endothelial cells (HUVEC) [19].
In conclusion, the present study shows that the expres-
sion pattern of the angiogenic-related genes from OECs of
ischemic patents changes during their expansion but pre-
serves the pro-angiogenic potential despite the ischemic
insult. Therefore, it would be of great value to determine
in which differentiation stage (i.e., whether colony or
mature) would OECs be more effective in cell-based
therapies, making them an attractive tool to be tested for
autologous transplantation after ischemic stroke.
This study certainly includes some limitations. We
included stroke patients between 24 h and 7 days after
onset of symptoms because we demonstrated in a previ-
ous study that OECs from subacute strokes (obtained
after 24 h of the symptoms onset) showed a higher ex-
pression and secretion of angiogenic factors than OECs
obtained in the first hours following stroke [4]. However,
the temporal profile of OECs maturation in terms of
angiogenic factors gene expression needs to be confirmed
at different time points in a larger cohort of stroke
patients. We focused our study in ischemic stroke
patients because cell cultures from sex- and age-matched
controls did not yield OECs under the same cell culture
conditions. In this regard, we have already demonstrated
that circulating EPCs are reduced in control subjects
compared to stroke patients [4]. Moreover, other authors
have shown that hormonal status influences circulating
EPC levels being significantly reduced in postmenopausal
women related to reduce estradiol levels [20]. Since our
control group was primarily composed by women in
menopausal age (76.5%, 70.6±7.4 years old) this could
also partially explain our difficulty. Finally, it would be
interesting to compare gene expression patterns of OECs
with those of primary endothelial cells. However, the ad-
vantage of using hCMEC/D3 cells is that they model the
human blood brain barrier (BBB) and avoid the inherent
variability as well as the difficulty of sourcing that apply
to primary endothelial cultures. Further studies, must
confirmed our results in a larger number of patients and
further explored at functional level to define its biological
implications.Competing interest
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